Compare AstraZeneca plc (AZN) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? AstraZeneca plc trades at $158.72 (market cap $248.14B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11. The key difference: AstraZeneca plc pays a 2.01% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | GPTY | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $50.52 |
52-Week Low | $147.06 | $34.73 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
